Advertisement

Clinical features and management of venous thromboembolism in patients with Behçet’s syndrome: a single-center case–control study

  • Neera Toledo-Samaniego
  • Francisco Galeano-ValleEmail author
  • Blanca Pinilla-Llorente
  • Jorge Del-Toro-Cervera
  • Alberto Marra
  • Marco Proietti
  • Pablo Demelo-Rodríguez
IM - ORIGINAL
  • 19 Downloads

Abstract

Almost one third of patients with Behçet's syndrome (BS) display vascular involvement. However, data regarding the prevalence and management of venous thromboembolism (VTE) in BS are scanty. We assessed the differential characteristics between patients with and without VTE and the factors associated with VTE incidence. A case–control study in a cohort of patients with BS was performed. 57 patients were included (56.1% women) with a mean follow-up of 10.56 (± 10.7) years. Mean age at diagnosis of BS and diagnosis of the first VTE episode was 34.7 (± 12.1) and 31.2 (± 8.9) years, respectively. Erythema nodosum (OR 4.6, CI 95% 1.2–18.1) and fever (OR 8.2, CI 95% 1.6–42.1) were associated with a higher risk of VTE. 26 episodes of VTE were registered in 12/57 (21%) patients. 83.3% of patients were not diagnosed with BS when the first episode of VTE occurred and, among them, the episode of VTE led to the diagnosis of BS in 40% of cases. Half of patients had at least one VTE recurrence. The absence of immunosuppressive treatment was associated with a higher risk of developing a first episode of VTE (OR 20 CI 95% 19.2–166.6). All patients were treated with anticoagulation and 75% were treated with immunosuppressants after the first VTE event. The diagnosis of VTE usually precedes that of BS, with a high frequency of VTE recurrence. Erythema nodosum and fever were associated with a higher risk of VTE, while the immunosuppressants showed a protective role for the development of VTE.

Keywords

Behçet’s syndrome Immunosuppressive agents Corticosteroids Embolism 

Abbreviations

BS

Behçet’s syndrome

VTE

Venous thromboembolism

ISGBD

International Study Group for Behçet’s Disease

ITR-ICBD

International Team for the Revision of the International Criteria for Behçet's Disease

DVTLE

Deep venous thrombosis of lower extremities

SVT

Superficial venous thrombosis

ICV

Inferior cava vein

CECT

Contrast-enhanced computed tomography (CECT)

CTPA

Computed tomography pulmonary angiography (CTPA)

HLA

Human leukocyte antigen

ICBD

International criteria for BD

LEVT

Lower extremities venous thrombosis

DVT

Deep venous thrombosis

Notes

Author contributions

Conception and design: NT-S, FG-V. Administrative support: NT-S, FG-V. Provision of study materials or patients: NT-S, FG-V. Collection and assembly of data: NT-S, FG-V. Data analysis and interpretation: NT-S, FG-V, PD-R. Manuscript writing: NT-S, FG-V. Final approval of manuscript: all authors.

Funding

This research did not receive any specific Grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

The author(s) declare that they have no conflict of interest.

Statement of human and animal rights

This study was carried out following the international ethical recommendations for conducting research in humans in the latest revision of the Declaration of Helsinki, as well as those established in the Good Clinical Practice Guidelines and in the current legislation. The study was approved by the Institutional Ethics Committee (03/2019).

Informed consent

Informed consent was not requested because it was a retrospective study.

References

  1. 1.
    Yazici H, Seyahi E, Hatemi G, Yazici Y (2018) Behçet syndrome: a contemporary view. Nat Rev Rheumatol 14:107–119 (Erratum in Nat Rev Rheumatol. 2018 14:119) CrossRefGoogle Scholar
  2. 2.
    Seyahi E (2016) Behçet’s disease: how to diagnose and treat vascular involvement. Best Pract Res Clin Rheumatol [Internet] 30(2):279–295CrossRefGoogle Scholar
  3. 3.
    Emmi G, Silvestri E, Squatrito D, Prisco D, Emmi L (2014) Behçet’s syndrome pathophysiology and potential therapeutic targets. Intern Emerg Med 9:257–265CrossRefGoogle Scholar
  4. 4.
    Seyahi E (2019) Phenotypes in Behçet’s syndrome. Intern Emerg Med 14(5):677–689CrossRefGoogle Scholar
  5. 5.
    Emmi G, Bettiol A, Silvestri E, Di G, Matteo S, Claudia B et al (2018) Vascular Behçet’s syndrome: an update. Intern Emerg Med 14(5):645–652CrossRefGoogle Scholar
  6. 6.
    Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V et al (2003) The long-term mortality and morbidity of Behçet syndrome a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60–76CrossRefGoogle Scholar
  7. 7.
    Fabiani C, Vitale A, Orlando I, Sota J, Capozzoli M, Franceschini R et al (2017) Quality of life impairment in Behçet’s disease and realationship with disease activity: a prospective study. Intern Emerg Med 12:947–955CrossRefGoogle Scholar
  8. 8.
    Zeidan MJ, Saadoun D, Garrido M, Klatzmann D, Six A, Cacoub P (2016) Behçet's disease physiopathology: a contemporary review. Auto Immun Highlights 7:4CrossRefGoogle Scholar
  9. 9.
    Emmi G, Becatti M, Bettiol A, Hatemi G, Prisco D, Fiorillo C (2019) Behçet’s syndrome as a model of thrombo-inflammation: the role of neutrophils. Front Immunol 10:1085CrossRefGoogle Scholar
  10. 10.
    Becatti M, Emmi G, Silvestri E, Bruschi G, Ciucciarelli L, Squatrito D et al (2016) Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Behçet disease. Circulation 133:302–311CrossRefGoogle Scholar
  11. 11.
    Becatti M, Emmi G, Bettiol A, Silvestri E, Scala G, Taddei N et al (2019) Behçet's syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects. Clin Exp Imunol. 195(3):322–333CrossRefGoogle Scholar
  12. 12.
    Mantovani A, Cassatella MA, Constatini C, Jaillon S (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Inmunol 11:519–531CrossRefGoogle Scholar
  13. 13.
    Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F et al (2018) 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis 77(6):808–818PubMedGoogle Scholar
  14. 14.
    Fei Y, Li X, Lin S, Song X, Wu O, Zhu Y et al (2013) Major vascular involvement in Behçet's disease: a retrospective study of 796 patients. Clin Rheumatol 32:845–852CrossRefGoogle Scholar
  15. 15.
    Seyahi E, Yazici H (2015) Behçet’s syndrome : pulmonary vascular disease. Curr Opin Rheumatol 27:18–23CrossRefGoogle Scholar
  16. 16.
    International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080Google Scholar
  17. 17.
    Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, Schirmer M et al (2014) International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28:338–347CrossRefGoogle Scholar
  18. 18.
    Rodríguez-Carballeira M, Solans R, Larrañaga JR, García-Hernández FJ, Ríos-Fernández R, Nieto J et al (2018) Venous thrombosis and relapses in patients with Behçet’s disease. Descriptive analysis from Spanish network of Behçet’s disease (REGEB cohort). Autoimmune Diseases Study Group (GEAS). Clin Exp Rheumatol 36((6 Suppl 115)):40–44PubMedGoogle Scholar
  19. 19.
    Alibaz-Oner F, Karadeniz A, Yılmaz S, Balkarlı A, Kimyon G, Yazıcı A et al (2015) Behçet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses. Med Baltim 94:e494CrossRefGoogle Scholar
  20. 20.
    Desbois AC, Wechsler B, Resche-Rigon M, Piette JC, Huong Dle T, Amoura Z et al (2012) Immunosuppressants reduce venous thrombosis relapse in Behçet's disease. Arthritis Rheum 64:2753–2760CrossRefGoogle Scholar
  21. 21.
    Wu X, Li G, Huang X, Wang L, Liu W, Zhao Y et al (2014) Behçet’s disease complicated with thrombosis a report of 93 Chinese cases. Medicine (Baltimore) 93(28):e263CrossRefGoogle Scholar
  22. 22.
    Tohmé A, Aoun N, El-Rassi B, Ghayad E (2003) Vascular manifestations of Behçet’s disease. Eighteen cases among 140 patients. Joint Bone Spine 70:384–389CrossRefGoogle Scholar
  23. 23.
    Tascilar K, Melikoglu M, Ugurlu S, Sut N, Caglar E, Yazici H et al (2018e) Vascular involvement in Behçet’s syndrome: a retrospective analysis of associations and the time course. Rheumatol Oxf 53:2018e22CrossRefGoogle Scholar
  24. 24.
    Galeano-Valle F, Demelo-Rodriguez P, Álvarez-Sala-Walther L, Pinilla-Llorente B, Echenagusia-Boyra MJ, Rodriguez-Abella H et al (2018) Intracardiac thrombosis in Behçet’s Disease successfully treated with immunosuppressive agents: a case of vascular pathergy phenomenon. Intractable Rare Dis Res 7(1):54–57CrossRefGoogle Scholar
  25. 25.
    Oblitas CM, Galeano-Valle F, Toledo-Samaniego N, Pinilla-Llorente B, Del Toro-Cervera J, Álvarez-Luque A et al (2019) Budd-Chiari syndrome in Behçet's disease successfully managed with immunosuppressive and anticoagulant therapy: a case report and literature review. Intractable Rare Dis Res 8(1):60–66CrossRefGoogle Scholar
  26. 26.
    Ahn JK, Lee YS, Jeon CH, Koh EM, Cha HS (2008) Treatment of venous thrombosis associated with Behcet’s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 27:201–205CrossRefGoogle Scholar
  27. 27.
    Tayer-Shifman OE, Seyahi E, Nowatzky J, Ben-Chetrit E (2012) Major vessel thrombosis in Behçet’s disease: the dilemma of anticoagulant therapy—the approach of rheumatologists from different countries. Clin Exp Rheumatol 30:735–740PubMedGoogle Scholar
  28. 28.
    Hamuryudan V, Er T, Seyahi E, Akman C, Tüzün H, Fresko I et al (2004) Pulmonary artery aneurysm in Behçet syndrome. Am J Medd 117:867–870CrossRefGoogle Scholar

Copyright information

© Società Italiana di Medicina Interna (SIMI) 2019

Authors and Affiliations

  • Neera Toledo-Samaniego
    • 1
    • 2
    • 3
  • Francisco Galeano-Valle
    • 1
    • 2
    • 3
    Email author
  • Blanca Pinilla-Llorente
    • 1
    • 2
    • 3
  • Jorge Del-Toro-Cervera
    • 1
    • 2
    • 3
  • Alberto Marra
    • 4
  • Marco Proietti
    • 5
    • 6
  • Pablo Demelo-Rodríguez
    • 1
    • 2
    • 3
  1. 1.Venous Thromboembolism Unit, Department of Internal MedicineHospital General Universitario Gregorio MarañónMadridSpain
  2. 2.School of MedicineUniversidad Complutense de MadridMadridSpain
  3. 3.Instituto de Investigación Sanitaria Gregorio MarañónMadridSpain
  4. 4.Department of Cardiovascular ImagingIRCCS (Istituto Di Ricovero E Cura a Carattere Scientifico)-SDN Research InstituteBariItaly
  5. 5.Department of NeuroscienceIstituto Di Ricerche Farmacologiche Mario Negri IRCCSMilanItaly
  6. 6.Department of Internal Medicine and Medical SpecialtiesSapienza University of RomeRomeItaly

Personalised recommendations